Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice

Medicine & Life Sciences

• Macular Edema 100%
• Vascular Endothelial Growth Factor A 67%
• Adrenal Cortex Hormones 42%
• Lasers 34%
• Cerebrovascular Disorders 27%
• Confidence Intervals 25%
• Myocardial Infarction 18%
• Propensity Score 18%
• Hemorrhage 16%
• Drug Therapy 15%
• Therapeutics 14%
• Medicare Part C 13%
• Hospitalization 12%
• Databases 10%
• Light Coagulation 10%
• Selection Bias 9%
• Insurance 8%
• Standard of Care 8%
• Comorbidity 6%
• Cohort Studies 5%
• Retrospective Studies 5%
• Health Care Outcome Assessment 5%
• Demography 5%
• Safety 5%